Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma

Details

Files
Generic Name:
Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma
Project Status:
Pending
Project Line:
Reimbursement Review
Project Sub Line:
Therapeutic Review
Project Number:
TR0014-000 - OP0547-000
Effective finish date:

Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. However, at this time, the optimal sequence of therapies is unclear. CADTH is preparing a Therapeutic Review considering multiple MM drugs and treatment steps in order to help decision-makers develop appropriate pharmaceutical funding policies.

Key Milestones
Draft recommendation(s) posted for stakeholder feedback January 4, 2024
End of feedback period January 25, 2024
Updated Draft recommendation(s) posted for stakeholder feedback March 7, 2024
End of feedback period March 21, 2024